Follicular lymphoma classification
Follicular lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Follicular lymphoma classification On the Web |
American Roentgen Ray Society Images of Follicular lymphoma classification |
Risk calculators and risk factors for Follicular lymphoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
According to the World Health Organization (WHO), follicular lymphoma may be classified into 3 subtypes: low grade follicular lymphoma, high grade follicular lymphoma, and diffuse large B cell lymphoma. Three variants of follicular lymphoma include pediatric follicular lymphoma, primary intestinal follicular lymphoma, and other extranodal follicular lymphoma.
Classification
1- Morphological Classification
The World Health Organization (WHO) classifies follicular lymphoma as follows[1]:
- Grades 1 and 2 now as low grade follicular lymphoma
- Grade 3A as high grade follicular lymphoma
- Grade 3B as diffuse large B cell lymphoma
2- Variants of Follicular Lymphoma
Follicular lymphoma has 3 variants that include the following:[2]
A. Pediatric follicular lymphoma
- Involves cervical lymph nodes, other peripheral lymph nodes, or Waldeyer ring
- Typically have early stage disease
- Lacks bcl-2 protein expression and t(14;18)
B. Primary intestinal follicular lymphoma
- Occurs most commonly in the small intestine, and frequently involves the duodenum
- Duodenal follicular lymphoma
- Found in the second portion of the duodenum
- Present as multiple polyps
- Diagnosis is most often an incidental finding
- Most patients have localized disease
- Prognosis is excellent even without treatment
C. Other extranodal follicular lymphomas
- Usually have localized extranodal disease
- Systemic relapses are rare
- Testicular follicular lymphoma are reported with increased frequency in children, but also are reported in adults.
References
- ↑ "Follicular Lymphomas". Retrieved 2008-07-26.
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov